Table 1 Patient Characteristics of the pPCL cohort compared to a previously published MM cohort17,18.
Patient clinical characteristics | pPCL (n = 23) | MM (n = 1273) | p value |
|---|---|---|---|
Median age at diagnosis (Min−Max) | 59 (36–77) | 66 (27–93) | |
Age ≥ 65 years (%) | 9/23 (39%) | 693/1273 (54%) | NS |
Isotype (Kappa/Lambda) | 11/12 | — | |
ISS stage I (%) | 0/23 (0%) | 360/1170 (31%) | <0.01 |
ISS stage II (%) | 1/23 (4%) | 442/1170 (38%) | <0.01 |
ISS stage III (%) | 22/23 (96%) | 368/1170 (31%) | <0.0001 |
Elevated LDH (%) | 13/17 (76%) | — | |
Elevated creatinine (≥2 mg/dL) | 18/22 (81%) | — | |
t(11;14) | 5/23 (22%) | 234/1273 (18%) | NS |
t(14;16) or t(14;20) | 10/23 (43%) | 62/1273 (5%) | <0.0001 |
t(4;14) | 2/23 (9%) | 58/461 (13%) | NS |
Hyperdiploidy | 3/23 (13%) | 456/1074 (42%) | <0.01 |
Gain of chromosome 1q | 17/23 (74%) | 314/1074 (29%) | <0.0001 |
1q duplication (=3 copies) | 13/23 (57%) | — | |
1q amplification (≥4 copies) | 4/23 (17%) | — | |
C-Myc translocations | |||
Ig partner loci (IGH, IGK, IGL) | 5/23 (22%) | 202/751 (27%) | NS |
Non-Ig partner loci (FAM46C, MYNN, SPARC, QRSL1, PLXNA4, CDH7, RNF123) | 9/23 (39%) | — |
